Revenue: $558.6 million in Q1 2025, a 9.3% year-over-year increase. Net New Business Awards: $500 million, a decrease of 18.8% from the prior year. Ending Backlog: Approximately $2.8 billion as of March 31, 2025, a decrease of 2.1% from the prior year. Backlog Conversion: 19.2% of beginning backlog in Q1 2025. EBITDA: $118.6 million, a 2.6% increase from Q1 2024. EBITDA Margin: 21.2%, down from 22.6% in the prior year period. Net Income: $114.6 million, an 11.7% increase from the prior year period. Net Income per Diluted Share: $3.67, up from $3.20 in the prior year period. Cash Flow from Operating Activities: $125.8 million in Q1 2025. Cash Balance: $441.4 million as of March 31, 2025. Share Repurchase: Approximately 1.19 million shares for $389.8 million in Q1 2025. 2025 Revenue Guidance: $2.14 billion to $2.24 billion, growth of 1.5% to 6.2% over 2024. 2025 EBITDA Guidance: $462 million to $492 million, a decline of 3.8% to growth of 2.5% compared to 2024. 2025 Net Income Guidance: $378 million to $402 million. 2025 Earnings per Diluted Share Guidance: $12.26 to $13.04.

Warning! GuruFocus has detected 8 Warning Signs with WKEY.

Release Date: April 22, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Revenue for the first quarter of 2025 was $558.6 million, representing a year-over-year increase of 9.3%. Net income for the first quarter increased by 11.7% compared to the prior year, reaching $114.6 million. Medpace Holdings Inc (NASDAQ:MEDP) generated $125.8 million in cash flow from operating activities during the first quarter. The company repurchased approximately 1.19 million shares for $389.8 million, indicating strong capital return to shareholders. Guidance for full-year 2025 revenue is expected to be in the range of $2.14 billion to $2.24 billion, showing potential growth over 2024.

Negative Points

Net new business awards entering backlog in the first quarter decreased by 18.8% from the prior year. The net book-to-bill ratio was 0.90, indicating a decline in new business relative to revenue. Backlog cancellations were modestly elevated, with pre-backlog cancellations being significantly worse. EBITDA margin for the first quarter was 21.2%, down from 22.6% in the prior year period. The company faces increased price competition and variability in the quality of RFPs, impacting business decisions.

Q & A Highlights

Q: Are you seeing more price competition in RFPs, and is this affecting the quality of RFPs? A: Yes, there is more price competition, especially during industry slowdowns. This results in more CROs being invited to bid, which can increase RFP numbers. However, the quality of RFPs is affected by unfunded projects seeking proposals to secure funding, leading to a worsening in RFP quality. (August Troendle, CEO)

Story Continues

Q: What would be required to achieve a 1.15 book-to-bill ratio in the second half of the year? A: Achieving a 1.15 book-to-bill ratio depends on reducing cancellations and improving the business climate. We have visibility into opportunities that could convert into backlog, but this requires projects to move into execution and avoiding large cancellations. (August Troendle, CEO)

Q: What impact could a stable environment have on bookings and revenue for the second half of the year? A: In a stable environment, we might see a book-to-bill ratio around 1.0. Revenue for the second half is mostly locked in, but there is still some risk due to potential client funding difficulties. We don't have a model for 2026 yet. (August Troendle, CEO)

Q: Can you provide more details on the cancellation trends and their impact? A: Cancellations have been broad, largely due to funding issues, but also include reprioritization and drug safety concerns. We don't disclose specific cancellation rates but discuss trends and magnitudes. (August Troendle, CEO)

Q: How is Medpace responding to increased competition in the biotech CRO landscape? A: We haven't seen a significant change in competitive dynamics. Our approach remains focused on providing personalized services, and we haven't made changes in response to competitors restructuring their approach. (August Troendle, CEO)

Q: What factors contributed to the higher revenue growth in Q1, and how sustainable is this growth? A: The higher revenue growth was influenced by increased reimbursable cost activity and better-than-expected program progression. This was more timing-related, and we expect reimbursable costs to stabilize at similar levels to the back half of 2024. (Kevin Brady, CFO)

Q: How are funding issues affecting client commitments and project cancellations? A: Clients often represent having funding arranged, but commitments can be weak, leading to funding issues. This is part of the dynamic causing project cancellations, particularly in pre-backlog stages. (August Troendle, CEO)

Q: What is the outlook for headcount growth given the current environment? A: We are targeting mid-single-digit headcount growth this year, but this will depend on how the business environment unfolds. If conditions improve, we may accelerate hiring. (Jesse Geiger, President)

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments